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Definitions  are  important  and  help 
shape how medical science develops. The 
Latin  name  ‘materia  medica’  described 
  therapeutically-useful  materials  (plants, 
animals and minerals) and the term evolved 
into  the  word  ‘pharmacology’,  defined 
by  the  British  Pharmacology  Society  as 
the study of drugs and the way in which 
they work. In this new journal we need 
to broaden the definition to include the 
functions of naturally-occurring media-
tors such as neurotransmitters, cytokines 
and hormones, ‘tool compounds’ and the 
development  of  structure-activity  rela-
tionships, the characterization of new anti-
bodies and fusion proteins, and even the 
actions of bacteria, provided the cell-cell 
interactions can be characterized.
The  gastrointestinal  (GI)  tract  is  an 
extraordinary world. It represents a huge 
interface between the external environ-
ment and the systems which sustain our 
existence  (the  surface  area  of  mucosal 
villae of the human gut is equivalent to 
that of a football pitch). It helps orches-
trate the delivery of food into itself and 
assists in how this is utilized. Thus, as the 
largest endocrine organ in the body, the 
gut uses hormones together with its own 
intrinsic and extrinsic nervous systems, to 
help promote appetite (eg. via the release 
of ghrelin and other hormones from the 
stomach) and potentiate glucose-depend-
ent  insulin  secretion  from  islet  β-cells 
(via GLP-1; glucagon-like peptide 1). It 
defends itself from bad selections of food, 
sometimes by releasing 5-HT (>90% of 
total  mammalian  body  5-HT  is  found 
in  enterochromaffin  cells  where  it  can 
induce vomiting or diarrhea) and always 
via its own extensive immune system (the 
number of lymphocytes within the gut-
associated  lymphoid  system  for  exam-
ple, is roughly equivalent to the spleen). 
Digestion begins with an incredibly toxic 
mix of acid and proteases in the stomach. 
Movements of the GI tract are control-
led mostly by the intrinsic (enteric) nerv-
ous system which in terms of   numbers 
of nerve cells is   comparable to the spinal 
cord.  Control  is  further  achieved  by  a 
large number of different GI hormones, 
operating on the enteric and vagal nerve 
systems to modulate GI movements as well 
as influence satiety and certain aspects of 
metabolism. Final stages of digestion and 
absorption take place in the colon where 
the huge colony of bacteria (the bacterial 
gene compliment of the gut exceeds that of 
the human body, with a metabolic capac-
ity in the same range as the liver) ferment 
unabsorbed carbohydrates and proteins. 
The bacteria also have a symbiotic rela-
tionship with the mammalian body, affect-
ing  colonic  development,  inflammation 
and factors as diverse as weight gain and 
anxiety; potentially harmful interactions 
between the bacteria and the gut are regu-
lated by the immune system but break-
downs in regulation can lead to disease.
The complex interactions between dif-
ferent systems of the gut and between the 
gut and the rest of the body suggest that it is 
not always reasonable to study these differ-
ent mechanisms in isolation. One challenge 
to GI scientists, faced with organizational 
‘reductionism’ is to remember this com-
plexity and integrate disciplines such as 
‘neuroscience’,  ‘  immuno-inflammation’ 
and  ‘metabolism’  (and  even  ‘bacteriol-
ogy’), back into gastroenterology. Failure 
to do so slows down the recognition that 
some pathological conditions which are 
not  obviously  gastrointestinal  in  origin 
can, however, be controlled by modulat-
ing GI function. A simple and dramatic 
example of what has been missed, until 
recently, is the discovery that diabetes in 
the obese can be reduced by surgical rear-
rangement of the gut, so food is made to 
bypass most of the stomach and upper 
small intestine.
There is always a need to embrace new 
technologies and a second challenge for 
GI pharmacologists is to stay involved. To 
some extent, the GI functions of recently 
‘de-orphanised’ G-protein-coupled recep-
tors  have  been  investigated,  but  much 
remains to be done; the same is also true 
for the wide range of innate and adap-
tive mucosal immune mechanisms which 
still need to be evaluated in the gut. GI 
pharmacologists  need  to  be  involved 
in  the  characterization  of  monoclonal 
antibodies or Fc-fusion proteins used to 
modify GI functions (especially when the 
immunoglobulin is fused to the binding 
region of the receptor). Further, as major 
advances in epigenetics are beginning to 
open new ways in which complex func-
tional disorders (such as irritable bowel 
syndrome)  might  be  treated,  GI  phar-
macologists have a role to play in char-
acterizing compounds which manipulate 
epigenetic modifications; assays need to be 
designed, for example, to demonstrate effi-
cacy in native, therapeutically-relevant cell 
systems. Equally challenging is the need to 
find ways of defining the mechanisms by 
which probiotic formulations or specific 
bacteria affect GI function and then design 
assays to characterize the actions of one 
type of bacteria – or bacterial product - 
over another.
This is a GI pharmacology journal. It 
can help ‘bridge the gap’ between gastro-
enterology and pharmacology, by describ-
ing the new science which is sometimes 
too specialized or too immature to find 
its  way  into  gastroenterology  journals, 
yet is relevant to GI science. It must also 
be inclusive and bring all relevant sub-
specialties of GI science onto a single gas-
trointestinal  platform.  It  needs  to  cross 
traditional boundaries of ‘neuroscience’, 
‘immunology’ and ‘metabolism’, so studies 
on gastric acid secretion, gastrointestinal 
motility and secretion sit alongside studies 
on mechanisms of GI sensations (such as 
taste, appetite, nausea and pain), immune 
regulation and inflammation. All aspects 
of translation will be important, includ-
ing  comparisons  between  recombinant 
and  native  receptor  functions,  between 
animal and human biology and between 
in vitro predictions and in vivo efficacy. 
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promise to revolutionize how we study GI 
functions and disease. Finally, there is a need 
to build a platform in which GI pharma-
cologists can come together. It is to be hoped 
that this journal will play at least some role 
in meeting this challenge.
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issue, in view of the continued use of ani-
mal models of pain in spite of their failure 
to translate across to the clinic.
In  conclusion,  three  over-riding  chal-
lenges have been identified. There is a need 
to  remember  that  the  GI  tract  does  not 
exist in isolation but has major influences 
on the rest of the body. There is a need to 
embrace new technologies, some of which 